Australian Pharmaceutical Industries (ASX:API) share price down 5% on half year results

The Australian Pharmaceutical Industries Ltd (ASX:API) share price is under pressure on Thursday after releasing its half year results…
The post Australian Pharmaceutical Industries (ASX:API) share price down 5% on half year results appeared first on The Motley Fool Australia. –

falling healthcare asx share represented by doctor with head in hands

The Australian Pharmaceutical Industries Ltd (ASX: API) share price is dropping today following the release of its half year results.

At the time of writing, the pharmacy chain operator and distributor’s shares are down 5% to $1.28.

How did Australian Pharmaceutical Industries perform in the first half?

For the six months ended 31 March, the Priceline pharmacy owner reported a 2.6% decline in total revenue to $2 billion.

Things were much worse for its earnings, with underlying earnings before interest and tax (EBIT) falling 26.5% on the prior corresponding period to $32 million.

And on the bottom line it was a similar story, with underlying net profit after tax falling 30.3% to $17.7 million.

This led to the company declaring an interim dividend of 1.5 cents per share, which is down sharply on FY 2019’s interim dividend of 3.8 cents per share. Australian Pharmaceutical Industries didin’t pay a dividend in the first half of FY 2020 due to COVID-19.

What were the drivers of this result?

The main drag on its performance was its Retail business, which reported a 10.7% decline in revenue to $526 million and an 8% reduction in gross profit to $103 million.

The company’s Pharmacy Distribution performed better. It reported steady revenue at $1.46 billion and a small increase in gross profit to $114 million.


No guidance was given for the full year. However, management commented that it remains confident about the growth potential of its two retail businesses and the reliability of its Pharmacy Distribution cash-generating business.

The company’s CEO and Managing Director, Richard Vincent, said: “We’ve taken the necessary measures to ensure we have the balance sheet to grasp all the growth opportunities that we’ve identified for our existing businesses and to make any additional moves that we deem will increase shareholder value. Our suburban retail businesses have rebounded strongly since COVID restrictions have eased and our negotiations with CBD landlords to achieve acceptable rental outcomes are ongoing.”

“We’ve made significant digital investments in the last year to prepare Priceline Pharmacy for growth, including in online shopping, instore health technologies, re-engineering our market leading loyalty program and securing new and exclusive product offerings and there will be further investments in this space over the next twelve months. Our strong track record in effectively managing flu vaccinations means we are better placed than most to quickly roll out COVID vaccinations. We’re incredibly conscious of the responsibility we have to get the rollout right to reduce the risk of COVID breakouts in our community,” he added.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Australian Pharmaceutical Industries (ASX:API) share price down 5% on half year results appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!